OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Marcus Flather graduated from the Royal Free Hospital School of Medicine and trained in general medicine and cardiology in London and Oxford. In 1988 he joined CTSU at the University of Oxford, working on large clinical trials in acute coronary syndromes, and continued this work at McMaster University from 1993-1996 before being appointed Director of the Clinical Trials and Evaluation Unit and Consultant Cardiologist at Royal Brompton and Harefield Hospitals.
In September 2011 he was appointed Professor of Medicine and Clinical Trials at the University of East Anglia and Director of Research at the Norfolk and Norwich University Hospitals NHS Foundation Trust in Norwich. He is a recognised expert in clinical trials and has more than 20 years’ experience collaborating with academic and industry partners in drug and device development.
In this seminar, Professor Flather will discuss results from the recently published CANTOS trial in which canakinumab therapy yielded benefit for both cardiovascular and cancer outcomes.
